Abbott raises annual earnings outlook as COVID-19 test sales rebound
Reuters
Published Oct 20, 2021 07:38AM ET
Updated Oct 20, 2021 11:17AM ET
By Mrinalika Roy and Carl O'Donnell
(Reuters) - Abbott Laboratories (NYSE:ABT) said demand for its COVID-19 tests, especially rapid testing, rebounded as the U.S. wrestled with surging coronavirus cases during the quarter, prompting the company to raise its earnings forecast for the year.
The medical device maker's shares rose 3.5% to $123.53 on Wednesday after it also reported third-quarter earnings above analysts' estimates.
The company said it shipped more than 225 million COVID-19 tests globally in the quarter and expects testing to remain an important part of the fight against the virus going into the fourth quarter and 2022.
"Over the last several months, we've learned that COVID-19 vaccines, while a powerful tool, are not the lone solution needed in our global fight against this virus," Chief Executive Officer Robert Ford said.
"Testing, particularly rapid testing, which is fast, affordable and easy to use is an important companion to vaccines and therapeutics."
Abbott and other diagnostics companies have seen higher demand for COVID-19 tests in recent months due to the Delta variant of the virus.
The U.S. government has also announced policies aimed at pushing large employers to have their workers inoculated or tested weekly and invested around $3 billion to procure rapid COVID-19 tests from Abbott and other manufacturers.
The company expects coronavirus test-related sales to be between $1.0 billion and $1.4 billion in the fourth quarter.
In the short term, through the traditional flu season testing volumes will likely remain robust, but this revenue boost could be transitory, Atlantic Equities analyst James Mainwaring said.
Abbott raised its outlook for 2021 adjusted earnings from continuing operations to between $5.00 and $5.10 per share, compared with its previous forecast of $4.30 to $4.50 per share.
On an adjusted basis, the company earned $1.40 per share, beating estimates of 95 cents per share, according to Refinitiv IBES data.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.